Association of the genetic ancestry with resistant hypertension in the ReHOT (Resistant Hypertension Optimal Treatment) randomized study

Autor(es)

Bueno, Carolina Tosin ^[1] ; Pereira, Alexandre Costa ^[1] ; Santos, Hadassa Campos ^[1] ; Gomez Gomez, Luz Marina ^[1] ; Vancan Russo Horimoto, Andrea Roseli ^[1] ; Krieger, Eduardo Moacyr ^[1] ; Krieger, Jose Eduardo ^[1] ; Lima Santos, Paulo Caleb Junior ^[2]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Heart Inst, Lab Genet & Mol Cardiol, Med Sch, Sao Paulo - Brazil

^[2] Univ Fed Sao Paulo EPM, Escola Paulista Med, Unifesp, Dept Pharmacol, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: SCIENTIFIC REPORTS; v. 10, n. 1 JAN 30 2020.
• Citações Web of Science: 0

Resumo

Resistant hypertension (RH) is defined as uncontrolled blood pressure despite treatment with three or more antihypertensive medications, including, if tolerated, a diuretic in adequate doses. It has been widely known that race is associated with blood pressure control. However, intense debate persists as to whether this is solely explained by unadjusted socioeconomical variables or genetic variation. In this scenario, the main aim was to evaluate the association between genetic ancestry and resistant hypertension in a large sample from a multicenter trial of stage II hypertension, the ReHOT study. Samples from 1,358 patients were analyzed, of which 167 were defined as resistant hypertensive. Genetic ancestry was defined using a panel of 192 polymorphic markers. The genetic ancestry was similar in resistant (52.0% European, 36.7% African and 11.3% Amerindian) and nonresistant hypertensive patients (54.0% European, 34.4% African and 11.6% Amerindian) (p>0.05). However, we observed a statistically suggestive association of African ancestry with resistant hypertension in brown patient group. In conclusion, increased African genetic ancestry was not associated with RH in Brazilian patients from a prospective randomized hypertension clinical trial. (AU)

• Processo FAPESP: 13/09295-3 - Avaliação farmacogenética para fármacos do sistema cardiovascular com foco na implementação
• Beneficiário: Paulo Caleb Júnior de Lima Santos
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores
• Processo FAPESP: 13/24440-0 - Avaliação farmacogenética e farmacometabolômica para fármacos anti-hipertensivos
• Beneficiário: Carolina Tosin Bueno
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto